KaydedilenlerDerginizi ekleyin

Dergiler / Afet ve Risk Dergisi / 2021 / Cilt: 4 Sayı: 2

Biyolojik Afetler: 2021'in İlk Çeyreğinde Covid-19 Pandemisine Genel Bir Bakış

Biological Disasters: An Overview of the Covid-19 Pandemic in the First Quarter of 2021

Yakup Artik(Türkiye Sağlık Enstitüleri Başkanlığı, TUSEB)0000-0002-2636-4879
Nevra Cesur(Türkiye Sağlık Enstitüleri Başkanlığı, TUSEB)0000-0003-3979-6053
Levent Kenar(SAVUNMA SAĞLIK BİLİMLERİ ENSTİTÜSÜ TIBBİ KİMYASAL BİYOLOJİK RADYOLOJİK VE NÜKLEER SAVUNMA ANABİLİM DALI)0000-0002-6613-1308
Mesut Ortatatlı(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ/SAVUNMA SAĞLIK BİLİMLERİ ENSTİTÜSÜ/TIBBİ KİMYASAL BİYOLOJİK RADYOLOJİK VE NÜKLEER SAVUNMA ANABİLİM DALI)0000-0002-7899-6157
Sayfa
163–182
Yayın Tarihi
2021-11-30
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bu araştırma çalışmasında 2021 yılına genel bir bakış sağlamak amacıyla verilerin analizini, ölüm oranlarını ve aşılamada gelinen noktayı bu zaman çizelgesi içinde değerlendirmeye çalıştık.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Afet, doğal veya insan kaynaklı, aniden gelişen, kontrol edilebilirliği sistematik bir yaklaşım gerektiren, sosyal hayatı kesintiye uğratan veya durduran, can, mal kaybına neden olan ve çoğu zaman yerel kapasite ile üstesinden gelinemeyen bütünsel bir durum olarak tanımlanmaktadır.
📊
Temel Bulgular & Veri:Biyolojik afetler insan kaynaklı olabileceği gibi, doğal olarak bulaşıcı hastalıklar ve epidemiyolojik olarak da ortaya çıkabilmektedir. 21. yüzyılın potansiyeli düşünüldüğünde, Domuz Gribi (H1N1), Kuş Gribi (H5N1) ve Corona virüs ailesi gibi grip enfeksiyonlarında biyolojik afetler rol oynamıştır.
💡
Sonuç & Katkı:Bu araştırma çalışmasında 2021 yılına genel bir bakış sağlamak amacıyla verilerin analizini, ölüm oranlarını ve aşılamada gelinen noktayı bu zaman çizelgesi içinde değerlendirmeye çalıştık.
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:Biyolojik Afet · Covid-19 · SARS-CoV-2

Özet

Afet, doğal veya insan kaynaklı, aniden gelişen, kontrol edilebilirliği sistematik bir yaklaşım gerektiren, sosyal hayatı kesintiye uğratan veya durduran, can, mal kaybına neden olan ve çoğu zaman yerel kapasite ile üstesinden gelinemeyen bütünsel bir durum olarak tanımlanmaktadır. Biyolojik afetler insan kaynaklı olabileceği gibi, doğal olarak bulaşıcı hastalıklar ve epidemiyolojik olarak da ortaya çıkabilmektedir. 21. yüzyılın potansiyeli düşünüldüğünde, Domuz Gribi (H1N1), Kuş Gribi (H5N1) ve Corona virüs ailesi gibi grip enfeksiyonlarında biyolojik afetler rol oynamıştır. Tıbbi KBRN ajanlarının etkili olduğu afetler göz önünde bulundurularak biyolojik afetlerin risk yönetiminin belirlenmesi amacıyla bu çalışmadaki verileri risk yönetimi açısından değerlendirdik. Dünya Sağlık Örgütü'nün (DSÖ) 11 Mart 2020 tarihi ile pandemi ilan etmesinin üzerinden bir yılı aşkın bir süre geçmesi sonucunda vakaların toplam kümülatif sırasına göre listede ilk 15 ülke yer aldı ve 2021 yılının ilk çeyreğinde SARS-CoV-2 haftalık vakası belirlendi. Bu araştırma çalışmasında 2021 yılına genel bir bakış sağlamak amacıyla verilerin analizini, ölüm oranlarını ve aşılamada gelinen noktayı bu zaman çizelgesi içinde değerlendirmeye çalıştık.

Abstract

Disaster is defined as the holistic state of natural or human-induced events that develop suddenly, whose controllability requires a systematic approach, which interrupts or stops social life and causes loss of life, property and often cannot be overcome with local capacity. Biological disasters can be human-induced as well as naturally infectious diseases and epidemiological emergencies. Considering the potential of the 21st century, biological disasters have played a role in influenza infections such as Swine Flu (H1N1), Bird Influenza (H5N1), and the Coronavirus family. Considering the disasters in which medical CBRN agents are effective, we evaluated the data in this study to determine the risk management of biological disasters. Since the World Health Organization (WHO) declared a pandemic on March 11, 2020, the first 15 countries are included in the list based on the total cumulative order of the cases and the 12-week case of SARS-CoV-2 in the first quarter of 2021. We tried to evaluate the analysis of data, mortality rates, and the point reached in vaccination within this timeline to provide an overview of 2021 in this research study.

🔖

Bu Makaleye Atıf Yap

Artik, Y., Cesur, N., Kenar, L., Ortatatlı, M. (2021). Biyolojik Afetler: 2021'in İlk Çeyreğinde Covid-19 Pandemisine Genel Bir Bakış. Afet ve Risk Dergisi, Cilt: 4 Sayı: 2, 163–182. https://doi.org/10.35341/afet.977488

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (62)

  1. Achaiah, N. C., Subbarajasetty, S. B., & Shetty, R. M. (2020). R0 and Re of COVID-19: Can We Predict When the Pandemic Outbreak will be Contained? Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine, 24(11), 1125. https://doi.org/10.5005/jp-journals-10071-23649
  2. Agrawal, A. S., Tao, X., Algaissi, A., Garron, T., Narayanan, K., Peng, B.-H., Couch, R. B., & Tseng, C.-T. K. (2016). Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Human Vaccines & Immunotherapeutics, 12(9), 2351–2356. https://doi.org/https://doi.org/10.1080/21645515.2016.1177688
  3. Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., Tao, Q., Sun, Z., & Xia, L. (2020). Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. https://doi.org/10.1148/radiol.2020200642
  4. Akgül, M. Ş., Ozcan, N., Uzun, M. E., Gurses, V. V, & Baydil, B. (2021). Physiological impact of wearing a surgical face mask during walking in the COVID-19 pandemic. Pedagogy of Physical Culture and Sports, 25(4), 202–207. https://doi.org/10.15561/26649837.2021.0401
  5. Alauddin, M., Khan, F., Imtiaz, S., Ahmed, S., & Amyotte, P. (2021). Pandemic risk management using engineering safety principles. Process Safety and Environmental Protection, 150, 416–432. https://doi.org/10.1016/j.psep.2021.04.014
  6. Ansart, S., Pelat, C., Boelle, P. Y., Carrat, F., Flahault, A., & Valleron, A. J. (2009). Mortality burden of the 1918-1919 influenza pandemic in Europe. Influenza and Other Respiratory Viruses, 3(3), 99–106. https://doi.org/10.1111/j.1750-2659.2009.00080.x
  7. Bauch, C. T. (2021). Estimating the COVID-19 R number: a bargain with the devil? In The Lancet Infectious Diseases (Vol. 21, Issue 2, pp. 151–153). Elsevier. https://doi.org/10.1016/S1473-3099(20)30840-9
  8. Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., & Sachs, D. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181(5), 1036–1045. https://doi.org/https://doi.org/10.1016/j.cell.2020.04.026
  9. Bland, S. A. (2014). Chemical, Biological, Radiological and Nuclear (CBRN) Casualty Management Principles. In Conflict and Catastrophe Medicine (pp. 747–770). Springer. https://doi.org/Doi 10.1007/978-1-4471-2927-1_46
  10. Cunningham, A. C., Goh, H. P., & Koh, D. (2020). Treatment of COVID-19: old tricks for new challenges. Springer. https://doi.org/10.1186/s13054-020-2818-6
  11. Daniloski, Z., Jordan, T. X., Wessels, H. H., Hoagland, D. A., Kasela, S., Legut, M., Maniatis, S., Mimitou, E. P., Lu, L., Geller, E., Danziger, O., Rosenberg, B. R., Phatnani, H., Smibert, P., Lappalainen, T., TenOever, B. R., & Sanjana, N. E. (2021). Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell, 184(1), 92-105.e16. https://doi.org/10.1016/j.cell.2020.10.030 Di Mascio, D., Khalil, A., Saccone, G., Rizzo, G., Buca, D., Liberati, M., Vecchiet, J., Nappi, L., Scambia, G., Berghella, V., & D’Antonio, F. (2020). Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. American Journal of Obstetrics & Gynecology MFM, 2(2), 100107. https://doi.org/10.1016/j.ajogmf.2020.100107
  12. Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases, 20, doi.org/10.1016/S1473-3099(20)3012. https://doi.org/doi.org/10.1016/S1473-3099(20)30120-1
  13. Feng, G., Zheng, K. I., Yan, Q.-Q., Rios, R. S., Targher, G., Byrne, C. D., Van Poucke, S., Liu, W.-Y., & Zheng, M.-H. (2020). COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. Journal of Clinical and Translational Hepatology, 8(1), 18. https://doi.org/10.14218/JCTH.2020.00018
  14. Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Dela Cruz, C. S., Wang, Y., Wu, C., Xiao, Y., Zhang, L., Han, L., Dang, S., Xu, Y., Yang, Q. W., Xu, S. Y., Zhu, H. D., Xu, Y. C., Jin, Q., … Wang, J. (2020). Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa310
  15. Hashem, A. M., Algaissi, A., Agrawal, A. S., Al-Amri, S. S., Alhabbab, R. Y., Sohrab, S. S., S. Almasoud, A., Alharbi, N. K., Peng, B.-H., & Russell, M. (2019). A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. The Journal of Infectious Diseases, 220(10), 1558–1567. https://doi.org/https://doi.org/10.1093/infdis/jiz137
  16. Hsieh, K. Y., Kao, W. T., Li, D. J., Lu, W. C., Tsai, K. Y., Chen, W. J., Chou, L. S., Huang, J. J., Hsu, S. T., & Chou, F. H. C. (2021). Mental health in biological disasters: From SARS to COVID-19. In International Journal of Social Psychiatry (Vol. 67, Issue 5, pp. 576–586). SAGE Publications Sage UK: London, England. https://doi.org/10.1177/0020764020944200
  17. Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 19(3), 141–154. https://doi.org/https://doi.org/10.1038/ s41579-020-00459-7
  18. Jasper J. et al. (2017). GISAID Global Initiative on Sharing All Influenza Data. Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) - BOOK. In Oxford (Vol. 34, Issue 8). https://www.researchgate.net/publication/321428915_SAPP_functional_genome_annotation_and_analysis_through_a_semantic_framework_using_FAIR_principles
  19. Johnson, N. P. A. S., & Mueller, J. (2002). Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bulletin of the History of Medicine, 76(1), 105–115. https://doi.org/10.1353/bhm.2002.0022
  20. Khabbaz, R., Bell, B. P., Schuchat, A., Ostroff, S. M., Moseley, R., Levitt, A., & Hughes, J. M. (2014). Emerging and Reemerging Infectious Disease Threats. In Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (Vol. 1, pp. 158–177). Elsevier. https://doi.org/10.1016/B978-1-4557-4801-3.00014-X
  21. Komurcu, S. Z. M., Artik, Y., Cesur, N. P., Tanriverdi, A., Erdogan, D. C., Celik, S., & Gulec, E. Y. (2021). The Evaluation Potential Global Impact Of The N501Y Mutation In Sars-Cov-2 Positive Patients. Journal of Medical Virology. https://doi.org/10.1002/JMV.27413
  22. Kwok, K. O., Lai, F., Wei, W. I., Wong, S. Y. S., & Tang, J. W. T. (2020). Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries. In Journal of Infection (Vol. 80, Issue 6, pp. e32–e33). https://doi.org/10.1016/j.jinf.2020.03.027
  23. Kwon, E. H., Reisler, R. B., Cardile, A. P., Cieslak, T. J., D’Onofrio, M. J., Hewlett, A. L., Martins, K. A., Ritchie, C., & Kortepeter, M. G. (2018). Distinguishing Respiratory Features of Category A/B Potential Bioterrorism Agents from Community-Acquired Pneumonia. In Health Security (Vol. 16, Issue 4, pp. 224–238). Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA. https://doi.org/10.1089/hs.2018.0017
  24. Lam, W. K., Zhong, N. S., & Tan, W. C. (2003). Overview on SARS in Asia and the World. In Respirology (Vol. 8). https://doi.org/10.1046/j.1440-1843.2003.00516.x
  25. Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., & Wang, F. (2020). Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature Medicine, 26(6), 842–844. https://doi.org/https://doi.org/10.1038/s41591-020-0901-9
  26. Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., & Tan, Z. (2019). Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight, 4(4). https://doi.org/https://doi.org/10.1172/jci.insight.123158
  27. Macnaughton, M. R., & Davies, H. A. (1987). Coronaviridae. Perspectives in Medical Virology. https://doi.org/10.1016/S0168-7069(08)70094-6
  28. Manning, F. J., & Goldfrank, L. (2002). Preparing for terrorism: tools for evaluating the metropolitan medical response system program. National Academies Press (US). https://doi.org/https://doi.org/10.17226/10412
  29. Mitjà, O., & Clotet, B. (2020). Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health, 8(5), e639–e640. https://doi.org/10.1016/S2214-109X(20)30114-5
  30. Morens, D. M., Folkers, G. K., & Fauci, A. S. (2008). Emerging infections: a perpetual challenge. The Lancet Infectious Diseases, 8(11), 710–719. https://doi.org/10.1016/S1473-3099(08)70256-1
  31. Niska, R. W., & Burt, C. W. (2005). Bioterrorism and Mass Casualty Preparedness in Hospitals, United States, 2003, BOOK. (Issue 364). US Department of Health and Human Services, Centers for Disease Control.
  32. Omer, S. B., Yildirim, I., & Forman, H. P. (2020). Herd Immunity and Implications for SARS-CoV-2 Control. JAMA, 324(20), 2095–2096. https://doi.org/10.1001/jama.2020.20892
  33. Özceylan Aubrecht, D., & Coşkun, E. (2014). Kimyasal, biyolojik, radyolojik, nükleer (KBRN) Afetlere gerçek zamanlı yanıt sağlayacak bir karar destek sistemi modeli. Yönetim Bilişim Sistemleri Kongresi, 49.
  34. Pehlivan, D., Bayram, Y., Gunes, N., Coban Akdemir, Z., Shukla, A., Bierhals, T., Tabakci, B., Sahin, Y., Gezdirici, A., Fatih, J. M., Gulec, E. Y., Yesil, G., Punetha, J., Ocak, Z., Grochowski, C. M., Karaca, E., Albayrak, H. M., Radhakrishnan, P., Erdem, H. B., … Lupski, J. R. (2019). The Genomics of Arthrogryposis, a Complex Trait: Candidate Genes and Further Evidence for Oligogenic Inheritance. American Journal of Human Genetics, 105(1), 132–150. https://doi.org/10.1016/j.ajhg.2019.05.015
  35. Public Health England. (2020). Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 Technical Briefing 3. In Gov.Uk, BOOK (Issue December). https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201
  36. Remy, K. E., Mazer, M., Striker, D. A., Ellebedy, A. H., Walton, A. H., Unsinger, J., Blood, T. M., Mudd, P. A., Yi, D. J., & Mannion, D. A. (2020). Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight, 5(17). https://doi.org/https://doi.org/10.1172/jci.insight.140329
  37. Schirmbeck, R., Böhm, W., & Reimann, J. (1996). Virus-like particles induce MHC class I-restricted T-cell responses. Intervirology, 39(1–2), 111–119. https://doi.org/https://doi.org/10.1159/000150482
  38. Sezen, F. (2009). Influenza pandemics. Türk Hijyen ve Deneysel Biyoloji Dergisi, 66(2, Supplement), 21–24.
  39. Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020). Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 117(21). https://doi.org/10.1073/pnas.2003138117
  40. Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. In Journal of Advanced Research (Vol. 24, pp. 91–98). Cairo University. https://doi.org/10.1016/j.jare.2020.03.005
  41. Shu, Y., & McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data–from vision to reality. Eurosurveillance, 22(13), 30494. https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494
  42. Simonsen, L., Clarke, M. J., Schonberger, L. B., Arden, N. H., Cox, N. J., & Fukuda, K. (1998). Pandemic versus epidemic influenza mortality: A pattern of changing age distribution. Journal of Infectious Diseases, 178(1), 53–60. https://doi.org/10.1086/515616
  43. Spengler, J. R., Ervin, E. D., Towner, J. S., Rollin, P. E., & Nichol, S. T. (2016). Perspectives on West Africa Ebola virus disease outbreak, 2013–2016. Emerging Infectious Diseases, 22(6), 956–963. https://doi.org/10.32032/eid2206.160021
  44. Tirupathi, R., Bharathidasan, K., Palabindala, V., Salim, S. A., & Al-Tawfiq, J. A. (2020). Comprehensive review of mask utility and challenges during the COVID-19 pandemic. Infez Med, 28(suppl 1), 57–63. https://doi.org/Apsent
  45. Turan, C., & Hacımustafaoğlu, M. (2020). What is the R0 number and clinical significance in infectious diseases? In Cocuk Enfeksiyon Dergisi (Vol. 14, Issue 1, pp. e47–e48). https://doi.org/10.5578/ced.202008
  46. Türsen, Ü., Türsen, B., & Lotti, T. (2020). Cutaneous sıde‐effects of the potential COVID‐19 drugs. Dermatologic Therapy, 33(4), e13476. https://doi.org/10.1111/dth.13476
  47. URL 1, https://www.cdc.gov/anthrax/bioterrorism/index.htm (Last acceded: 11.09.2021). (n.d.). https://www.cdc.gov/anthrax/bioterrorism/index.htm (Last acceded: 11.09.2021)
  48. URL 2, https://emergency.cdc.gov/agent (Last Acceded: 11.09.2021). (n.d.).
  49. URL 3, https://apnews.com/article/united-nations-coronavirus-pandemic-china-only-on-ap-bats-24fbadc58cee3a40bca2ddf7a14d2955 (Last Acceded: 11.09.2021). (n.d.).
  50. URL 4, https://covid19.who.intv (Last Acceded: 11.09.2021), H. who. int., Https://covid19.who.int/region/amro/country/. (n.d.).
  51. Varol, N., & Buluş Kırıkkaya, E. (2017). Afetler Karşısında Toplum Dirençliliği. Resilience. https://doi.org/10.32569/resilience.344784
  52. Vellingiri, B., Jayaramayya, K., Iyer, M., Narayanasamy, A., Govindasamy, V., Giridharan, B., Ganesan, S., Venugopal, A., Venkatesan, D., Ganesan, H., Rajagopalan, K., Rahman, P. K. S. M., Cho, S. G., Kumar, N. S., & Subramaniam, M. D. (2020). COVID-19: A promising cure for the global panic. In Science of the Total Environment. https://doi.org/10.1016/j.scitotenv.2020.138277
  53. Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., Rey, S. M., Nicholls, S. M., Colquhoun, R. M., da Silva Filipe, A., Shepherd, J., Pascall, D. J., Shah, R., Jesudason, N., Li, K., … Connor, T. R. (2020). Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. MedRxiv, 184(1), 64–75. https://doi.org/10.1016/j.ygeno.2020.09.028
  54. Wang, R., Hozumi, Y., Yin, C., & Wei, G. W. (2020). Mutations on COVID-19 diagnostic targets. Genomics, 112(6), 5204–5213. https://doi.org/10.1016/j.ygeno.2020.09.028
  55. WHO. (2020). Draft landscape and tracker of COVID-19 candidate vaccines. In Who (Issue June). https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate
  56. Workgroup, C. D. C. S. P. (2000). Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. In MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, BOOK (Vol. 49, Issue RR-4).
  57. Wu, Zhiwei, Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., & Chen, P. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, 21(6), 803–812. https://doi.org/10.1016/S1473-3099(20)30987-7
  58. Wu, Zunyou, & McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama, 323(13), 1239–1242. https://doi.org/10.1001/jama.2020.2648
  59. Yilmaz Gulec, E., Cesur, N. P., Yesilyurt Fazlioğlu, G., & Kazezoğlu, C. (n.d.). Effect of different storage conditions on COVID‐19 RT‐PCR results. Journal of Medical Virology. https://doi.org/10.1002/jmv.27204
  60. Zhou, P., Yang, X. Lou, Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. Di, Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., … Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7
  61. URL 4, https://covid19.who.intv (Last Acceded: 11.09.2021), H. who. int., Https://covid19.who.int/region/amro/country/. (n.d.).
  62. Workgroup, C. D. C. S. P. (2000). Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. In MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, BOOK (Vol. 49, Issue RR-4).